

CURRICULUM VITAE**DAVID S.H. BELL, M.B., FACP, FRCPUK(Ed), FRCPS(Canada), FACE**

Business Address:
1900 Crestwood Blvd
Suite 201
Irondale, AL 35210

Clinic Telephone: (205)957.0034
Clinic Fax: (205)957.0036
Cell: (205)910.8773
E-mail: dshbell@yahoo.com

Birthplace: Armagh N. Ireland
Citizenship: USA
Married Status: Married
Children: Three

EDUCATION: **Belfast Royal Academy, 1955-1962**
 Queens University, Belfast Dental School, 1962-1965
 Queens University School of Medicine, 1965-1970
 Graduated MB, B. Ch., B.A.O., 1970

POSTGRADUATE TRAINING

Intern in Medicine, Royal Victoria Hospital, Belfast, N. Ireland, 1970-1971
Resident in Internal Medicine, Royal Victoria Hospital, Belfast, N. Ireland, 1971-1973
Resident in Internal Medicine, Royal University Hospital, Saskatoon, Saskatchewan, Canada, 1973-74
Fellow in Endocrinology, Royal University Hospital, Saskatoon, Saskatchewan, Canada, 1974-1975
Fellow in Endocrinology, Greater Baltimore Medical Center and John Hopkins Hospital, Baltimore Md, USA, 1975-1976

FACULTY POSITIONS HELD

Tutor in Medicine, Queens University, Belfast, 1971-1972
Tutor in Pharmacology and Therapeutics, Queens University, Belfast, 1972-1973
Teaching Fellow, University of Saskatchewan, Saskatoon, 1974-1975
Assistant Professor of Medicine, Temple University School of Medicine, 1978-1980
Clinical Assistant Professor of Medicine, Pennsylvania State University College of Medicine 1978-1980
Associate Professor of Medicine, University of Alabama at Birmingham, 1980-1987
Professor of Medicine, University of Alabama at Birmingham School of Medicine 1987-2005

David S.H. Bell

**Adjunct Clinical Professor of Medicine, University of Alabama Medical School,
Birmingham, AL 2005-present**

HONORS

2nd in Class Final Part 1 – 1969

Top 20 in Class Final Part 2 - 1970

Fellow, Royal College of Physicians and Surgeons of Canada, 1976

Fellow, American College of Physicians – 1983

Fellow, Royal College of Physicians of Edinburgh – 1986

Birmingham’s Best Doctors -2008-2015

Named in the “The Best Doctors in America”, 2001-2015

Named one of America’s Top Doctors, 2001-2015

Top Doctors for men in Men’s Health, 2007

Top Doctors for women in Women’s Health, 2008

Received the 2001 Distinguished Clinician award from the American College of Endocrinology for outstanding contribution to the field of Endocrinology as a master educator and clinician

Received the 2002 Southern Medical Association’s Seale Harris Award for superior contributions to the art and science of diabetes and endocrinology

Received in 2022 the Master of Clinical Endocrinology (MACE) from the American Association of Clinical Endocrinology awarded annually to a distinguished endocrinologist who is a role model for developing endocrinologists and a contributor to the art and science of endocrinology

Top 30% Reviewers for Annals of Internal Medicine -2008

USA Today Most Influential Doctors in Diabetes and Lipids - 2009

America's Most Compassionate Doctors - 2012

BOARD CERTIFICATION

Advanced Achievement in Internal Medicine, 1987

American Board of Internal Medicine (Endocrinology Subspecialty Certification), 1981

American Board of Internal Medicine, 1976

Royal College of Physicians and Surgeons of Canada, 1975

Royal College of Physicians of the United Kingdom, 1973

Professional Organizations

American College of Physicians, member 1977-1982, fellow 1983-present

Royal College of Physicians of Edinburgh, member 1973-1986, fellow 1986-present

Royal College of Physicians and Surgeons of Canada Fellow, 1976-present

Endocrine Society, 1990-present

American College of Endocrinology, 1994-Present

FACE 1994

Board of Directors, 2018-2021

David S.H. Bell

Professional Organizations(cont'd)

American Association of Clinical Endocrinologists, 1991-Present

Charter Member 1991

Board of Directors, 2014-2021

American College of Endocrinology

Board of Directors, 2018-2021

American Medical Association, 1978-Present

American Diabetes Association, 1978-Present

EDITORIAL BOARDS

Endocrine Practice 2000-2005

Southern Medical Journal 1998-2005

Treatments in Endocrinology 2001-2005

Diabetes Obesity and Metabolism 2002-present

Endocrine Today 2006-2021

Diabetes Therapy 2010-present

ADMINISTRATIVE APPOINTMENTS

District Coroner in Province of Ontario, 1976-1978

Conemaugh Valley Memorial Hospital, Johnstown PA

Vice Chairman of Medicine, 1978-1980

Director, Internal Medicine Residency Program, 1978-1980

Director, Physicians Continuing Education, 1978-1980

University of Alabama at Birmingham

Director of Clinical Services, Diabetes Research and Education Hospital, 1980-1992

Director Adolescent Diabetes Unit 1982-1985

Clinical Director, Endocrinology Clinic, The Kirklin Clinic, 1992-1997

Director, Clinical Research, Division of Endocrinology, 1998-2003

HOSPITAL APPOINTMENTS

Georgetown Memorial Hospital, Georgetown, Ontario, Canada 1976-1978

Conemaugh Valley Memorial Hospital, Johnstown, PA, 1978-1980

University of Alabama at Birmingham Hospital, 1980-2005

Eye Foundation Hospital, Birmingham, AL, 1981-1990

STATE LICENSURE:

General Medical Council of the United Kingdom 1970-1973

Saskatchewan, 1973-1975

Maryland, 1975-1976

Ontario, 1976-1981

Pennsylvania, 1978-1981

Alabama, 1980 – present (License #09301)

David S.H. Bell

PUBLICATIONS

1. Bell DSH, Moyer JH: Vasodilator drugs for peripheral vascular disturbances. In: Modell W (ed): *Drugs of Choice 1980-1981*. C.V. Mosby, St. Louis (1980)441-449.
2. Clements RS Jr, Bell DSH: Diagnostic pathogenetic and therapeutic aspects of diabetic neuropathy. In *Special Topics in Endocrinology and Metabolism*, Cohen M.P. and Foa P.P. (eds): A.R. Liss, Inc., New York, (1981)1-143.
3. Pittman W, Acton R, Barger B, Bell DSH, Go R, Murphy C, roseman J: HLA-A, -B, and -DR Associations in Type 1 Diabetes Mellitus with Onset After Age Forty. *Diabetes* (1982)31:122-125.
4. Clements RS Jr, Bell DSH: Diabetic Neuropathy. Peripheral and autonomic syndromes. *Postgraduate Medicine* (1982)71(6) 50-67.
5. Clements RS Jr, Bell DSH: Candidate mechanism for the pathogenesis of diabetic neuropathy. In: *Diabetes and its Late Complications*. Cudworth AG, Andreani D, Bodansky HJ, Squadrito G (eds): John Libbey, London (1982)119-126.
6. Fairclough PK, Clements RS Jr., Filer DV, Bell DSH: An evaluation of patient performance of and their satisfaction with various rapid blood glucose measurement systems. *Diabetes Care* (1983) 6:45-49.
7. Bell DSH, Clements RS Jr., : Reversal of the carpal tunnel syndrome after change of insulin injection sites. *Diabetes Care* (1983)6:45-46.
8. Bell DSH, Christian SR, Clements RS Jr.: Acuphobia in a long-standing insulin-dependent diabetic cured by hypnosis. *Diabetes Care* (1983) 6:622.
9. Bell DSH: Amitriptyline versus placebo in post-herpetic neuralgia. *Neurology* (1983) 33:1530.
10. Bell DSH: MIST: Medical Information via Telephone. *Alabama Journal of Medical Sciences* (1985) 22:311-314.
11. Bell DSH: Immunotherapy of Diabetes. *Dial Access of the Southern Medical Association*, 1984.
12. Bell DSH, Acton R: Immunotherapy of insulin-dependent diabetes. *Alabama Journal of Medical Sciences* (1985) 22:311-314.
13. Bell DSH: Exercise guidelines for the diabetic. *Sports and Medicina* (1985)5:31-33.

David S.H. Bell

14. **Hodge TW, Barger BO, Littrell MN, Bell DSH, Go RCP, Acton RT: DR-B restriction fragment length polymorphisms associated with insulin-dependent diabetes mellitus. Biochemical Society Transaction (1985)79(5A)1-7.**
15. **Clements RS Jr, Bell DSH: Diabetic complications – prevalence, detection, current treatment and prognosis. Amer J. Medicine (1985) 79(5A) 1-7.**
16. **Clements RS Jr, Bell DSH: Diabetic Neuropathy Part 1. Diabetic Complications (1985) 1:1-3.**
17. **Clements RS Jr, Bell DSH: Diabetic Neuropathy Part II. Diabetic Complications (1985) 2:1-4.**
18. **Bell DSH, Clements RS Jr: Selection of patients for insulin pump therapy. Practical Cardiology (1986) 12:57-71.**
19. **Clements RS Jr, Bell DSH: Intensive insulin therapy – rationale and methods. Research Update (1986) 1:1-8.**
20. **Bell DSH, Clements RS Jr.: Rapid insulin initiation in NIDDM: Effect on B-cell function and insulin resistance. Proceedings of 1st International Novo Symposium on Non-Insulin-Dependent Diabetes. Editor, R. Tattersal: (1987)61-66.**
21. **Clements RS Jr, Bell DSH, Benbarka A, Capper SA: Rapid insulin initiation in non-insulin dependent diabetes mellitus. Amer J. Medicine (1987)82:415-420.**
22. **Hughes TA, Clements RS, Fairclough PK, Bell DSH, Segrest JP: Effect of insulin therapy on lipoproteins in NIDDM. Atherosclerosis (1987) 67:105-114.**
23. **Bell DSH, Acton RT, Barger BO, Vanichanan C, Clements RS Jr.: The futility of predicting the onset of insulin-dependent diabetes. Diabetes Care (1987) 10:788-789.**
24. **Bell DSH, Clements RSJr.: Diabetes and the digestive system. Diabetes Forecast (1987)12:43-46.**
25. **Bartholomew G, Radu B, Bell DSH: Oral candidiasis in insulin-dependent diabetes. Diabetes Care (1987) 10:604-606.**
26. **Bell DSH, Ackerson C, Cutter G, Clements RSJr.: Factors associated with discontinuation of continuous subcutaneous insulin. American Journal of Medical Sciences (1988) 295:23-28.**

David S.H. Bell

27. Bell DS, Clements RS, Cutter GR, Whitley RJ. Condylomata acuminata in IDDM. *Diabetes Care* (1988) 11(3):295-6.
28. Bell DSH, Clements RS Jr.: Prediction and Immunosuppression of Type 1 Diabetes. Reply, *Diabetes Care* (1988) 11:511.
29. Bell DS. Failure to recognize that hypoglycemia may be a problem associated with insulin manufactured by the recombinant DNA method. *Clin Ther* 1989 11(5)707-708.
30. Bell DSH: Hypertension in the person with diabetes. *American Journal of Medical Sciences*. (1989) 297:228-232.
31. Lauritano AA, Clements RS, Bell DSH: Insulin antibodies in non-insulin-dependent diabetes mellitus: Effect of treatment with semi-synthetic human insulin. *Clinical Therapeutics* (1989) 2:268-277.
32. Bell DSH: Improved Treatment of NIDDM: Fixed-Ratio Insulin Regimens in: Making Life Better for the Insulin-Using Patient. A Special Report. *Postgraduate Medicine* (1989)10:27-34.
33. Bell DSH: Pathogenesis and Prevention of Insulin-Dependent Diabetes. Southern Medical Association, Dial Access Program, 1989.
34. Bell DSH: Pentoxifylline in the Treatment of Microcirculatory Disorders. A Review of the Literature. Ed. Bell DSH. Excerpta Medica Princeton, USA (1989)1-4.
35. Bell DSH: Topics in Clinical Research III. The importance of randomized, double-blind procedures in clinical trials. *Clinical Therapeutics* (1989)11(5) 652-658.
36. Clements RS Jr., Bell DSH. Increased responsiveness to exogenous insulin administration in the hypoglycemic obese person with type II diabetes. *Clinical Therapeutics* (1989) II(5) 652-658.
37. Bell DSH. The importance of double-blinding. *Clinical Therapeutics* (1989)11(5)707-708.
38. Bell DSH, Cutter GR, and Lauritano AA. Efficacy of a premixed semisynthetic insulin regimen. *Clinical Therapeutics* (1989)11:795-801.

David S.H. Bell

39. Acton RT, Vanichanan CJ, Perkins L, Go RCP, Roseman JM, Barger BO, Bell DSH, Goldenberg RL, Winkler CL, Tucker JM, Hauth JC, and Huddleston JF. **Immunogenetic Predictors of Gestational Diabetes in American Blacks in Immunology of Normal and Diabetic Pregnancy**, edited by D. Andreani, GD Bompiani, U Di Mario, S.P. Faulk and A. Galluzzo. John Wiley & Sons LTD (1990) Chapter 12, Pages 207-220.
40. Bell DSH. **Sulfonylurea failure in non-insulin-dependent diabetes mellitus. American Journal of Medicine (1990)89:446-447.**
41. Bell DSH, Clements RS Jr., Perentesis GP. **Hypoglycemia in children with insulin-dependent diabetes mellitus. J. Pediatr (1990) 117:340.**
42. Bell DSH, Barger BO, Go RCP, Goldenberg RL, Perkins LL, Vanichanan CJ, Roseman J, Acton RT. **Risk factors for gestational diabetes in the black population. Diabetes Care (1990) 13(11):1196-1201.**
43. Bell DSH. **Hazards of Inaccurate Readings Obtained by Self-Monitoring of Blood Glucose. Diabetes Care (1990) 13:1131-1132.**
44. Williams BT, Ketchum CH, Robinson A, and Bell DSH. **Screening for slight albuminuria: A comparison of selected commercially available methods. Southern Medical Journal (1990) 83:1447-1449.**
45. Bell DSH. **Diabetic nephropathy: Changing concepts of pathogenesis and treatment. The American Journal of the Medical Sciences (1991) 301:195-200.**
46. Tucker JM, Winkler CL, Hauth JC, Goldenberg RL, Acton RT, Barger BO, Go RCP, Bell DSH, Perkins LL, Vanichanan CJ, and Roseman JM. **Autoantibodies in black women with class A1 or class GB diabetes mellitus. American Journal of Perinatology (1991) 8:103-105.**
47. Winkler CL, Tucker JM, Hauth JC, Goldenberg RL, Acton RT, Barger BO, Go RCP, Bell DSH, Perkins LL, Vanichanan CJ, and Roseman JM. **Histocompatibility antigen subtypes in black women with class A1 or Class GB diabetes mellitus. American Journal of Perinatology (1991) 8:106-109.**
48. Bell DSH. **Lower limb problems in diabetic patients. What are the causes? What are the remedies? Postgraduate Medicine (1991) 89:237-244.**
49. Bell DSH, Bode B, Clements RS Jr., Herron J, Hollander P, Kumar D, Perentesis GP, Sosenko J. **Premixed vs. Self-mixed insulin in the treatment of type II diabetes mellitus: A randomized trial. Today's Therapeutic Trends. The Journal of New Developments in Clinical Medicine (1991) 9:63-73.**

David S.H. Bell

50. Bell DSH, Clements RS, Perentesis G, Roddam R, and Wagenknecht L. Dosage accuracy of self-mixed vs. premixed insulin. *Archives of Internal Medicine* (1991) 151:2265-2269.
51. Bell DSH, Wagenknecht LE. Effect of gemfibrozil on intermediate density lipoproteins in NIDDM patients. *Diabetes Care* (1992) 15:146-147.
52. Aikens JE, Wallander JL, Bell DSH, and Cole JA. Daily stress variability, learned resourcefulness, regimen adherence, and metabolic control in type 1 diabetes mellitus: Evaluation of a path model. *Journal of Consulting and Clinical Psychology* (1992) 60:113-118.
53. Roseman JM, Go RCP, Perkins L, Barger B, Bell DSH, Goldenberg RL, DuBard MB, Huddleston JF, Sedlacek CM, and Acton RT. Gestational diabetes mellitus among African-American women. *Diabetes/Metabolism Reviews* (1991) 93-104.
54. Bell DSH, Ketchum CH, Robinson CS, Wagenknecht LE, Williams BT. Microalbuminuria associated with diabetic neuropathy. *Diabetes Care* (1992) 15:528-531.
55. Bell DSH. Hypoglycemia induced by Enalapril in patient with insulin resistance and NIDDM. *Diabetes Care* (1992) 15:934-935.
56. Bell DSH. Milk allergy masquerading as insulin allergy. *Diabetes Care* (1992) 15:934-935.
57. Bell DSH. Diabetic nephropathy associated with insulin-dependent diabetes. *Internal Medicine* (2) (1992) Medifacts, Ottawa Canada.
58. Bell DSH. Exercise for patients with diabetes – benefits, risks, and precautions. *Postgraduate Medicine* (1992) 92:183-198.
59. Bell DSH, Cutter GR, Hayne VB, and Lloyd LK. Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in the diabetic male. *Urology* (1992) 40:36-40.
60. Bell DSH. Diabetic foot problems. *Family Practice* (1992) 2(6). Medifacts Ottawa, Canada.
61. Bell DSH. Diabetes and hypertension – prevalence and therapy. *Cardiology* (1992) (6). Medifacts Ottawa, Canada.

David S.H. Bell

62. Bell DSH, Cutter G, Clements RS, Jr. The feasibility of long-term treatment of diabetes with continuous subcutaneous insulin infusion. *Diab. Nutr. Metab.* (1993) 6:57-60.
63. Bell DSH. Insulin resistance: an often unrecognized problem accompanying chronic medical disorders. *Postgraduate Medicine* (1993) (937) 99-107.
64. Acton RT, Bell DSH, Go RC, Roseman J. Association of HLA phenotypes with hypertension in African Americans and Caucasoid Americans with type II diabetes, a population at risk for renal disease. *Transplant Proc* (1993) 25:2400-2403.
65. Bell DSH. The graveyard shift. *Diabetes Forecase* (1994) 47:47-49.
66. Chiu KC, Go RCP, Aoki M, Riggs AC, Tanizawa Y, Acton RT, Bell DSH, Goldenberg RL, Roseman JM, Permutt MA. Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning. *Diabetologia* (1994) 37:104-110.
67. Bell DSH. Stroke in the diabetic patient. *Diabetes Care* (1994) 17:217-219.
68. Bell DSH, Cutter G. Characteristics of severe hypoglycemia in the patient with insulin-dependent diabetes. *Southern Medical Journal* (1994) 87(6)616-620.
69. Bell DSH. Insulin pump therapy for the 90's. *The Endocrinologist* (1994) (4)270-278.
70. Acton RT, Roseman JM, Bell DSH, Goldenberg RL, Tseng ML, Vanichanan LA, Harman LA, Go RCP. Genes within the major histocompatibility complex predict NIDDM in African American Women in Alabama. *Diabetes Care* (1994) 17:1491-1494.
71. Bell DSH. Stopping those swinging sugars. *Diabetes Forecast* (1994)47:36-40.
72. Tanizawa Y, Riggs AC, Chiu KC, Janssen RC, Bell DSH, Go RPC, Roseman JM, Acton RT, Permutt MA. Variability of the pancreatic islet beta cell/liver (GLUT 2) glucose transporter gene in NIDDM patients. *Diabetologia* (1994) 420-427.
73. Aikens JE, Wallander JL, Bell DS, McNorton A. A nomothetic-idiographic study of daily psychological stress and blood glucose in women with type 1 diabetes mellitus. *J Behav Med* (1994) 17(6)535-48.
74. Bell DSH. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? *Diabetes Care* (1995) 18:708-714.

David S.H. Bell

75. Bell DSH. To hurt or not to hurt. *Diabetes Forecast* (1995) 48(6)30-33.
76. Bell DSH. How to manage stroke in patients with diabetes: Strategies for diagnosis, treatment and prevention. *The Journal of Critical Illness* (1995) 10(5)317-328.
77. Bell DSH. Myocardial infarction and stroke in diabetic patients. *Diabetes Metabolism*. (1995) 40:1-4.
78. Bell DSH. Lack of long-term diabetic complications in spite of poor glycemic control in twins with pure gonadal dysgenesis. *Diabetes Care* (1995) 18:1286-1287.
79. McCarren M, Bell DSH. Prepare to pump. *Diabetes Forecast* (1995) September 33-39.
80. Bell DSH, Grizzle WE, Dunlap NE. Nesidoblastosis causing reversal of insulin-dependent diabetes and development of hyperinsulinemic hypoglycemia. *Diabetes Care* (1995) 18:1379-1380.
81. Bell DSH. Night shift work and the diabetic patient. *The Endocrinologist* (1995) 5:344-346.
82. Bell DSH. Non-diabetic neuropathy in a patient with diabetes. *Endocrine Practice* (1995) 1(6) 393-394.
83. Bell DSH. A comparison of lovastatin, an HMG-COA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia. *Clinical Therapeutics* (1995) 17:901-910.
84. Bell DSH, Yumuk VD. Low incidence of false-positive exercise thallium 201 scintigraphy in a diabetic population. *Diabetes Care* (1995) 19(2)185.
85. Bell DSH. Profiles of stroke in the diabetic patient. *Advances in Cardiovascular Medicine* (1996) 3:1-8.
86. Bell DSH. Alcohol and the NIDDM patient. *Diabetes Care* (1996) 19:509-513.
87. Bell DSH. Myocardial infarction in the diabetic patient. *The Endocrinologist* (1996) 6:196-206.
88. Bell DSH, Acton RT. Increased prevalence of mitral valve prolapse in IDDM. *Diabetes Care* (1996) 19:672.

David S.H. Bell

89. **Bell DSH. Diabetes mellitus and coronary artery disease. *Coronary Artery Disease* (1996) 7(10)715-722.**
90. **Decrease in mortality from diabetic nephropathy in Pima Indians. *Diabetes Care* (1996) 19:779.**
91. **Bell DSH, Mayo MS. Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus. *Endocrine Practice* (1997) 3:73-76.**
92. **Bell DSH, Alele J. Diabetic ketoacidosis. *Postgraduate Medicine* (1997) 101:193-203.**
93. **Bell DSH. New modalities for the treatment of NIDDM: Acarbose and metformin. *Consultant Pharmacist* 12(suppl A)7-11,1997.**
94. **Bell DSH. Management of Diabetes: Medications. In *Diabetes Medical Nutrition Therapy*. Holler HJ, Pastors JG, Eds. The American Dietetic Association (1997) 35-42.**
95. **Bell DSH. Management of Diabetes: Complications. In *Diabetes Medical Nutrition Therapy*. Holler JH, Pastors JG, Eds. The American Dietetic Association (1997) 75-82.**
96. **Bell DSH. Diabetes mellitus and coronary artery disease. *Journal of Cardiovascular Risk* (1997) 4(2)83-90.**
97. **Bell DSH, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. *Endocrine Practice* (1997) 3:281-283.**
98. **Bell DSH. Converting patients with type 2 diabetes from insulin-requiring to non-insulin-requiring. *Clinical Diabetes* (1997) 15(5) 205-207.**
99. **Bell DSH. Reinitiation of oral hypoglycemic therapy – the Alabama Experience in *Proceedings of the Combined Insulin/Oral Agent Therapy: Satellite Symposium to the 1997 Postgraduate Meeting – Baylor College of Medicine, Houston, TX* (1997) 29-34.**
100. **Bell DSH. Effective Analgesia. *BMJ* (1997) 315:1411.**

David S.H. Bell

101. Acton RT, Bell DSH, Collins JN, Go RCP, Harrison R, McDonald R, Rivers C, Roseman JM, Taylor HA, and Vanichanan C. Genes within and flanking the major histocompatibility region are risk factors for diabetes, insulin resistance, hypertension, and microalbuminuria in African-American women. *Transplantation Proceedings* (1997) 29:3710-3712.
102. Bell DSH. University Group Diabetes Program – “Déjà vu all over again?” *Endocrine Practice* (1998) 4:6465.
103. Bell DSH, Mayo MS. Improved glycemic control with use of oral hypoglycemia therapy with or without insulin. *Endocrine Practice* (1998) 4(2):82-85.
104. Bell DSH. Managing type 2 diabetes patients who require insulin. In *Successful Strategies for the Control of Type 2 Diabetes*. Eds. Garber AJ, Bell DSH, Reasner C, James W. Postgraduate Institute for Medicine. Littleton, CO 1998 10-13.
105. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. *Endocrine Practice* (1998) 4:146-147.
106. Bell DSH, Kudlow J, Tidwell M. Health-care charges generated by patients with diabetes. *Endocrine Practice* (1998) 4:237-239.
107. Garber A, Bell DSH, Reasner C. *Successful Strategies for the control of type II Diabetes*. Baylor College of Medicine and Postgraduate Institute for Medicine. A Clinical Monograph. Editor, William E. James. 1998.
108. Bell DSH. Prudent utilization of the presently available treatment modalities for type 2 diabetes. *The Endocrinologist* (1998) 8:332-341.
109. Bell DSH, Ovalle F. Metformin lowers lipoprotein (a) levels. *Diabetes Care* (1998) 21:2028.
110. Bell DSH, Ovalle F. Troglitazone interferes with gemfibrozil’s lipid-lowering action. *Diabetes Care* (1998) 21:2028-2029.
111. Bell DSH, Mayo MS. Weight loss in patients treated with a metformin-sulfonylurea combination in comparison with twice daily mixed insulin. *Endocrine Practice* (1998) 4:360-364.
112. Bell DSH, Ovalle F. Using combination therapy for type 2 diabetes. *IM Internal Medicine* (1999) 20:20-27.
113. Bell DSH. Use of B-Adreneregic blocking agents with diabetes – friend and foe. *Endocrine Practice* (1999) 5:51-53.

David S.H. Bell

114. Bell DSH, Alele J. Dealing with diabetic nephropathy. *Postgraduate Medicine* (1999) 105:83-94.
115. Bell DSH, Ovalle F. Gastroparesis cured by gastrectomy. *Diabetes Care* (1999) 22(6)1000-1001.
116. Bell DSH, Ovalle F. C-peptide utilization in clinical practice: Effect on treatment and outcome of diabetes in a series of cases. *Endocrine Practice* (1999) 5(3):114-118.
117. Bell DSH, Ovalle F. Stroke management in the diabetic patient. *The Journal of Critical Illness* (1999) 14:309-318.
118. Ovalle F, Bell DSH. Troglitazone's effect on lipoprotein(a). *Diabetes Care* (1999) 22:859-860.
119. Bell DSH, Ovalle F. Is gastroparesis in diabetes cured by gastrectomy? Response to Schnedl et al. *Diabetes Care* (1999) 22:1921.
120. Bell DSH, Ovalle F. Advances in therapy for type 2 diabetes. *Patient Care* (1999) 33:189-200.
121. Ovalle F, Bell DSH. Hormone replacement therapy and serum uric acid. *Lancet* (1999) 354:1643-44.
122. Bell DSH, Ovalle F. Late-onset troglitazone-induced hepatic dysfunction. *Diabetes Care* (2000) 23:128-129.
123. Feld S, Hellman R, Dickey RA, Jellinger PS, Janick JJ, Rodbard HW, Cobin RH, Bell DSH, Ganda O, Davidson ET, Siebel JA. AACE Diabetes Guidelines. *Endocrine Practice* (2000) 6:42-84.
124. Bell DSH. Should anti-glutamic acid decarboxylase antibody levels be determined in new-onset diabetes? *Endocrine Practice* (2000) 6(2)214-216.
125. Bell DSH. Dunluce Castle, County Antrim, Northern Ireland. *The New England Journal of Medicine* (2000) 342(5)324.
126. Bell DSH. Inflammation, Insulin Resistance, Infection, Diabetes and Atherosclerosis. *Endocrine Practice* (2000)6:271-275.

David S.H. Bell

127. Bell DSH, Ovalle F. Diabetes as a Risk Factor for Ischemic Heart Disease. **Clinical Reviews – Prevention of Coronary Heart Disease: Identification and Treatment of Risk Factors.** Robert A. Kreisberg, M.D., Editor. (Spring 2000) 88-92.
128. Bell DSH, Ovalle F. Management of Type 2 Diabetes in Clinical Reviews – Prevention of Coronary Heart Disease: Identification and Treatment of Risk Factors. Robert A. Kreisberg, M.D., Editor (Spring 2000) 92-96.
129. Bell DSH, Ward J. Peripheral and Cranial Neuropathy in Diabetes. In **Clinical Diabetes Mellitus – Third Edition – John K. Davidson, M.D., Ph.D.** Thieme, N.Y., N.Y. (2000) 621-635.
130. Bell DSH, Ovalle F. How Long Can Insulin Be avoided in the Patient with Type 2 Diabetes Mellitus by Use of a Combination of Metformin and a Sulfonylurea? **Endocrine Practice (2000) 6:293-295.**
131. Bell DSH, Fowler MB. Comprehensive Adrenergic Blockade in Patients with Hypertension and Diabetes. **Cardiology Review (2000) 17:7(suppl)11-17.**
132. Bell DSH (ed.) Diabetes Insights. **Bioscience Reports (2000)1-8 Bioscience Communications NY, NY.**
133. Bell DSH. Cardiovascular Disease in South Asians. **Lancet (2000) 356:1109.**
134. Bell DSH. Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. (Letter)
135. Bell DSH, Ovalle F. Improved Glycemic Control with Use of Continuous Subcutaneous Insulin Infusion Compared with Multiple Insulin Injection Therapy. **Endocrine Practice (2000) 6:357-360.**
136. Bell DSH, Ovalle F, Shadmany S. Postprandial rather than preprandial glucose levels should be used for adjustment of rapid-acting insulins. **Endocrine Practice (2000) 6:477-478.**
137. Bell DSH. Pathophysiology of type 2 diabetes and its relationship to new therapeutic approaches. **Supplement to The Diabetes Educator Journal (2000)6:477-478.**
138. Bell DSH. Should angiotensin-converting enzyme inhibitors be added to the water supply of patients with diabetes? **Endocrine Practice (2001)7(1)59-63.**
139. Bell DSH. Ethics in Diabetic Clinical Trials. **Diabetes Care (2001)24(3):606.**

David S.H. Bell

140. Bell DSH, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: Review of the evidence in animals and humans. *Endocrine Practice* (2001)7(2):135-137.
141. Bell DSH, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. *Endocrine Practice* (2001)7(2):135-137.
142. Bell DSH, Ovalle F, Shadmany S. Cerebellar ataxia associated with high levels of anti-glutamic acid decarboxylase antibodies. *The Endocrinologist* (2001)11(3)233-235.
143. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone. *Endocrine Practice* (2001) 7:326.
144. Bell DSH. Importance of postprandial glucose control. *Southern Medical Journal* (2001) 94(8)804-809.
145. Go RCP, Desmond R, Roseman JM, Bell DSH, Vanichanan C, Acton RT. Prevalence and risk factors of microalbuminuria in a cohort of African-American women with gestational diabetes. *Diabetes Care* (2001)24:1764-1768.
146. Bell DSH. Drugs for cardiovascular risk reduction in the diabetic patient. *Current Diabetes Reports* (2001)1:133-139.
147. Acton RT, Barton JC, Bell DSH, Go RCP, Roseman JM. HFE mutations in African-American women with non-insulin-dependent diabetes mellitus. *Ethnicity and Disease* (2001)11:578-584.
148. Bell DSH. Combination therapy for type 2 diabetes. *American Family Physician* (2001)64(11)1812-1814.
149. Bell DSH. Current status of diabetes treatment. *Southern Medical Journal* (2002)95(1)24-29.
150. Bell DSH. Chronic complications of diabetes. *Southern Medical Journal* (2002)95(1)30-34.
151. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta cell function in patients with type 2 diabetes mellitus. *Diabetes, Obesity and Metabolism* (2002)4:56-59.
152. Bell DSH. Treatment of heart failure in patients with diabetes: clinical update. *Ethnicity and Disease* (2002)12(suppl 1) S1 12-18.

David S.H. Bell

153. Feld S, Hellman R, Dickey RA, Jellinger PS, Janick JJ, Robbard HW, Cobin RH, Bell DSH, Gand O, Davidson ET, Siebel JA. American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE System of Intensive Diabetes Self-Management – 2002 Update. *Endocrine Practice* (2002)8(suppl1)41-82.
154. Bode B, Weinstein R, Bell DSH, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt R. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. *Diabetes Care* (2002)25(3)439-444.
155. Ovalle F, Bell DSH. Effect of thiazolidinediones on high-density lipoprotein subfractions. *Endocrine Practice* (2002) 8(2)102-104.
156. Bell DSH. Understanding the role of insulin resistance for the treatment of diabetes and the reduction of cardiovascular risk. *Journal of Gender Specific Medicine* (2002)5:2(suppl 1)1-14.
157. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. *Endocrine Practice* (2002)8:271-275.
158. Albright ES, Ovalle F, Bell DSH. Artificially low hemoglobin A1c caused by use of dapson. *Endocrine Practice* (2002)8(5):370-372.
159. Bell DSH, Leahy JL, Piziak VK. Achieving glycemic control with insulin in type 2 diabetes. *Patient Care* (2002)36(12)60-83.
160. Bell DSH. Is diabetes a cardiovascular disease? *Cardiology Review* (2002)19(12)15-16.
161. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical practice. *Endocrine Practice* (2002)8(6)406-410.
162. Bell DSH, Albright ES, Ovalle F. High-dose mineralocorticoid requirements in an adrenally insufficient pregnant patient: A case report. *The Endocrinologist* (2002)12:391-394.
163. Gavin JR III, Bell DSH, Braunstein S, Henry R, Wyne K. Cardiovascular effects of insulin resistance: Beyond glycemic control. *Dialogues in Diabetes* (2003)3:1-15.
164. Bell DSH, Cross LB, Masood A, McGriff-Lee N. New Product Bulletin on Avandamet (rosiglitazone maleate and metformin Hcl) American Pharmaceutical Association (2002) 1-12.

David S.H. Bell

165. Albright ES, Bell DSH. The liver, liver disease, and diabetes mellitus. *The Endocrinologist* (2003)13:58-72.
166. Bell DSH. Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes. *Endocrine Practice* (2003)9:98-100.
167. Bell DSH. Beta-blockers in the diabetic patient. *Practical Diabetology* (2003) 22:20-23.
168. Nesto RW, Bell DSH, Dandona P, Goldstein BJ, Wyne KL. Type 2 diabetes and cardiovascular disease: Reducing the risks. *Dialogues in Diabetes* (2003) 3(4)1-15.
169. Bell DSH. Overview of 2002 AACE diabetes guidelines in Achieving Glycemic Control in Diabetes Mellitus. *Ingenix Fairfield NJ* 1-19.
170. Bell DSH. Use of beta blockers in the patient with diabetes. *The Endocrinologist* (2003)13(2):116-123.
171. Bell DSH. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus in A Special Report Reappraisal of Type 2 Diabetes Mellitus Management in Primary Care New Observations. A Postgraduate Medicine Special Report May 2003. Pages 35-52.
172. Wyne KL, Drexler AJ, Miller JL, Bell DSH, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes in a Special Report Reappraisal of Type 2 Diabetes Mellitus Management in Primary Care: New Observations. A Postgraduate Medicine Special Report. May 2003 Pages 63-72.
173. Nesto RW, Bell DSH, Dandona P, Goldstein BJ, Wyne KL. Type 2 diabetes and cardiovascular disease: reducing the risks. *Dialogues in Diabetes* (2003)3(5)1-14.
174. Bell DSH. Heart Failure. The frequent, forgotten, and often fatal complication of diabetes. *Diabetes Care* (2003) 26:2433-241.
175. Bell DSH. Maximally Utilizing the Available Agents for the Treatment of Type 2 Diabetes. *Clinical Medicine & Research* (2003) 1(3)173-174.
176. Bell DSH. Unilateral edema due to a thiazolidinedione. *Diabetes Care* (2003)26(9)2700.
177. Bell DSH. Diabetic Cardiomyopathy. *Diabetes Care* (2003)26:2949-2951.
178. Bell DSH. Functional class in patients with heart failure is associated with the development of diabetes. *Am J Med* (2003)115(5)412.

David S.H. Bell

- 179. Bell DSH, Rushakoff RJ. How to use combination drug therapy for type 2 diabetes. Patient Care (2003)37(9):33-44.**
- 180. Rubin RH, Bell DSH, Childs L, Felton AE, Garber A, Gavin J III, Kudhiro JK, Mora P, Penna P, Peyrot M, Raken R, Rodgers D. Type 2 diabetes: facing frustrations reversing resistance. Socratic Dialogues - a supplement to Internal Medicine News (2003)1-4.**
- 181. Korytkowski M, Bell DSH, Jacobsen C, Suwannasari R. For the Flex Pen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preferences, efficacy and safety profiles of a prefilled disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or type 2 diabetes mellitus. Clinical Therapeutics (2003)25(11)1-13.**
- 182. Rubin RH, Bell DSH, Childs L, Felton AE, Garber A, Gavin J III, Kudhiro JK, Mora P, Penna P, Peyrot M, Raken R, Rodgers D. Type 2 diabetes: facing frustrations reversing resistance. Socratic Dialogues a supplement to Family Practice News (2003) 1-4.**
- 183. Bell DSH. The importance of glucose control in the treatment of type 2 diabetes: focus on risk factor reduction. In Beneficial Effects of Glycemic Control on Macrovascular Complications of Type 2 Diabetes ed Bell DSH. Scientific Therapeutics Springfield, NJ (2003) Pages 1-7.**
- 184. Bell DSH, Blonde LA, Drexler AJ, Goldstein AJ, Goldstein BJ, Wyne KL, Meredith M. Diabetes and Cardiovascular Disease: Clinical Studies to Clinical Applications in Dialogues in Diabetes (2003) 3(4)1-15.**
- 185. Bell DSH. Dyslipidemia in type 2 diabetes and the effects of thiazolidinediones. The Endocrinologist (2003) 13:496-504.**
- 186. Albright ES, Bell DSH. Diabetic amyotrophy associated with hepatic virus C infection. The Endocrinologist (2003)13:445-448.**
- 187. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, LeWinter M, Porte D, Semenkovich CF, Smith S, Young CH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure? A consensus statement from the American Heart Association and American Diabetes Association. Circulation (2003) 108:2941-2948.**
- 188. Bell DSH. B-Cell rejuvenation with thiazolidinediones. The American Journal of Medicine (Proceedings of a Symposium) December 8, 2003 115(8A)20S-23S.**
- 189. Bell DSH. Therapy for Type 2 Diabetes (In response – Lett to the Editor) Endocrine Practice (2003)9(6):566-567.**

David S.H. Bell

- 190. Nesto RW, Bell DSH, Bonow RO, Fonseca V, Grundy SM, Horton ES, LeWinter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. *Diabetes Care* (2004)1(27):256-263.**
- 191. Bell DSH. Secretagogues and cardiac risk. *The Endocrinologist* (2004) 14:33-37.**
- 192. Bell DSH, Hardy RW, Desmond R. C-reactive protein and glycemic control in adults with diabetes. *Diabetes Care* (2004)27:637-638.**
- 193. Albright ES, Desmond R, Bell DSH. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin Glargine in Type 1 diabetic patients using basal/bolus therapy. *Diabetes Care* (2004)27:632-633.**
- 194. Bell DSH. Type 2 diabetes mellitus: What is the optimal treatment regimen? *AJM* (2004)116(Supplement 5A)23S-29S.**
- 195. Bell DSH. A comparison of agents used to manage type 2 diabetes mellitus. Need for reappraisal of traditional approaches. *Treatments in Endocrinology* (2004)3(2)67-76.**
- 196. Bell DSH. Thiazolidinedione-associated congestive heart failure and pulmonary edema. *Mayo Clin Proc* (2004)79:572.**
- 197. Bell DSH. Heart failure: A serious and common comorbidity of diabetes. *Clinical Diabetes* (2004)22(2)61-65.**
- 198. Bell DSH. Advantages of a third generation B-blocker in patients with diabetes mellitus. *American Journal of Cardiology* (2004)93(suppl)49B-52B.**
- 199. Bell DSH, Ovalle F. Outcomes of initiation of therapy with once daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. *Diabetes Obes Metab* (2004)6(5)363-366.**
- 200. Bell DSH, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. *Am J Ther* (2004)11(4)308-311.**
- 201. Bell DSH. Management of type 2 diabetes with thiazolidinediones. Link between B-cell preservation and durability of response. *The Endocrinologist* (2004)14(5)293-299.**
- 202. Bell DSH. Insulin as initial therapy for type 2 diabetes is not in the patient's best interest. *Endocrine Practice* (2004)10(3)208-212.**

David S.H. Bell

- 203. Wyne KL, Bell DS, Gambert SR. An algorithm for managing type 2 diabetes: A focus on the disease process, not just the sugar. A supplement to Annals of Long-Term Care (August, 2004)1-23.**
- 204. Bell DSH. Single-composition extended-release metformin hydrochloride. (Guest Commentary) Treatments in Endocrinology (2004)3(5)333.**
- 205. Wyne KL, Bell DSH, Gambert SR. An algorithm for managing type 2 diabetes: A focus on the disease process, not just the sugar. A Supplement to Clinical Geriatrics (August, 2004)1-21.**
- 206. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic B-Cell function of subjects with type 2 diabetes. Diabetes Care (2004) 27(11)2585-2589.**
- 207. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci (2004) 328(5)274-280**
- 208. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 292(18):2227-2236.**
- 209. Bell DSH. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combined therapy. Clinical Therapeutics (2004)26(11):1714-1727.**
- 210. Bell DSH. Treatment of type 2 diabetes with a combination of two insulin sensitizers – increased efficacy and fewer side-effects. Business Briefing: US Cardiology (2004)8:29-33.**
- 211. Bell DSH. Advances in diabetes for the millennium: the heart and diabetes. MedGenMed. (2004)6(2):7.**
- 212. O’Keefe JH, Bell DSH, Wyne KL, Haffner SM. Diabetes Essentials (2004) Physicians Press, Royal Oak, Michigan.**
- 213. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple, international trial of diabetes prevention: the DREAM trial. Diabetologia (2004)47:1519-1527.**

David S.H. Bell

214. Bakris GL, Bell DSH, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright, JT, Jr. Iyengar M, Holeslaw T, Anderson KM. The rationale and design of the glycemic effects in diabetes mellitus Carvedilol-Metoprolol comparison in hypertensives (GEMINI) trial. *Journal of Diabetes and Its Complications* (2005) 19:74-79.
215. Kirchheimer S, Bell DSH. Know your type 2 meds. *Diabetes Focus* (2005) 1(1) 24-26.
216. Bell, D. Latent autoimmune diabetes in adults (LADA). *Clinical Laboratory International* (2005) 29(2)12-14.
217. Prelipcean MS, O'Neil PJ, Bell DSH. Hyperinsulinemic Hypoglycemia, Precipitated by Weight Loss. *Southern Medical Journal* (2005) 98(7)726-728.
218. Abuissa H, Bell DSH, O'Keefe JH Jr. Strategies to prevent type 2 diabetes. *Current Medical Research and Opinions*. (2005) 21(7)1107-1114.
219. Bell DSH. Optimizing treatment of diabetes and cardiovascular disease with combined α,β -blockade. *Current Medical Research and Opinions* (2005)21(8)1191-1200.
220. Bell DSH. Latent autoimmune diabetes in adults (LADA). GAD in Metabolic and Neurologic Disease (2005) Vol II, DMCCAD, Stockholm, Sweden Pgs. 7-10.
221. Vaughan TB, Bell DSH. Statin neuropathy masquerading as diabetic autoimmune polyneuropathy. *Diabetes Care* (2005) 2082.
222. Drexler, AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell DSH, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the Cardiovascular Effects of Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in relation to the Metabolic Syndrome. *Metabolic Syndrome and Related Disorders* (2005)3(2)147-173.
223. Vaughan TB, Bell DSH. Stockpiling of ovarian follicles and the response to rosiglitazone. *Diabetes Care* (2005) 28(9)2333-2334.
224. Bell DSH, McGill JB. Carvedilol versus metoprolol in diabetic hypertensive patients. *Cardiology Review* (2005) 22(10)12-15.
225. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr., Waterhouse B, Lukas MA, Anderson KM, Bell DSH; for the GEMINI Investigators. Differential effects of β -blockers on albuminuria in patients with type 2 diabetes. *Hypertension* (2005)46:1309-1315.

David S.H. Bell

226. Bell, DSH. Differences between thiazolidinediones – Do the lipid effects really matter? *Metabolic Syndrome and Related Disorders* (2005)3(3):198-201.
227. Bell, DSH. The Diabetic Heart. *Journal of the Asian Federation of Endocrine Societies* (2005) 23(supplement 1)S7-S8.
228. Bell, DSH. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: a response to Goldberg, et al. *Diabetes Care* (2005)28(12)2983-2984.
229. O’Keefe JH, Bell DSH, Wyne KL, Haffner SM. *Diabetes Essentials* (2005) Physicians Press, Royal Oaks, Michigan.
230. Bell DS, Bakris GL. Carvedilol, metoprolol and insulin resistance – reply. *JAMA* (2005)293:1190.
231. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. *Diabetes Obes Metab* (2006)8(19):110-115.
232. Bell, DS. Do sulfonylurea drugs increase the risk of cardiac events? *CMAJ* (2006)174(2):185-186.
233. Bell, DSH. The effectiveness of β -blockers after myocardial infarction in patients with type 2 diabetes. Response to McDonald, et al. *Diabetes Care* (2006)29(2)483.
234. Bell DS, Lukas MA, Holdbrook FK, Fowler MB. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. *Curr Med Res Opin.* (2006)22(2):287-96.
235. Bell, DSH. Diabetic Hypertensive Pre-Heart Failure Patient in Heart Failure Clinics (2006)2(1) Bell, DSH (editor) Elsevier Saunders New York, New York XIII-XVI.
236. Vaughan TB, Bell DSH. Diabetic Cardiomyopathy in Heart Failure Clinics (2006)2(1) Bell DSH (editor) Elsevier Saunders New York, New York 71-80.
237. Bell, DSH. “Dead in bed syndrome – an hypothesis”. *Diabetes Obesity and Metabolism* (2006)8(3)261-263.
238. Bell, DS. The case for combination therapy as first-line treatment for the type 2 diabetic patient. *Treat Endocrinol.* 2006;5(3):131-7.
239. McGill JB, Bell DSH. Anemia and the roles of erythropoietin in diabetes. *J Diabetes Complications* (2006)20(4)262-272.

David S.H. Bell

240. Bell DSH, Wyne KL. Treatment of type 2 diabetes. Use of fixed-dose oral combinations. *Postgrad Med* (2006)119(2)8-14.
241. Bell DSH, Wyne KL. Treatment of type 2 diabetes. The addition of injection therapy. *Postgrad Med*(2006)119(2)15-20.
242. Bell DSH, McGill JB, Fonseca V. Impact of carvedilol on microalbuminuria is independent of the statin effect. *Diabetologia* (2006)49(supplement 1)640.
243. Bell, DSH. Hypertension, diabetes, insulin resistance, and postprandial hyperglycemia. *Drug Development Research* (2006)67(7)595-596.
244. The DREAM Trial Investigators. Effect of ramapril on the incidence of diabetes. *N Eng J Med* (2006)355:1551-1562.
245. The DREAM (Diabetes Reduction Assessment with ramapril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized, controlled trial. *Lancet* (2006)368:1096-1105.
246. Bell DSH, O'Keefe JH, Bakris GL. *Handbook of Diabetic Hypertension* (2006) Physicians Press, Royal Oaks, Michigan.
247. Bell, DS. Comment on: From the coalface: does glargine insulin improve hypoglycemic episodes, glycemic control or affect body mass in type 1 diabetic subjects who are attending a "routine" diabetic clinic? *Diabetologia* (2007)49:2793-2794.
248. McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS. Beta-Blocker use and diabetes symptom score: results from the GEMINI study. *Diabetes Obes Metab.* 2007 May;9(3):408-17.
249. Bell, DSH. Treatment of infertility in the polycystic ovary syndrome. *N Eng J Med* (2007)356:1999-2000.
250. O'Keefe JH, Bell DSH, Wyne KL, Haffner SM. *Diabetes Essentials – third edition* (2007) Physicians Press Royal Oak, Michigan.
251. Bell DSH. Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. *Endocr. Pract.* (2007)13:300-312.
252. Fonseca V, Bakris GL, Bell DSH, McGill JB, Raskin P, Messerli FH, Philips RA, Katholi RE, Wright JT, Waterhouse B, Lukas MA, Anderson KM. Differential effect of β -blocker therapy or insulin resistance as a function of insulin sensitizer use: results from GEMINI. *Diabetic Medicine* (2007)24(7)759-63.

David S.H. Bell

253. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT, Bangalore S, Holdbrook FK, Lucas MA, Anderson KM, Bakris GL; GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. *Am J Med* (2007)120(7):610-5.
254. Bell, DSH. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilized? *Drugs* (2007)67(13)1813-1827.
255. O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. *Am J Cardiol* (2007)100(5)899-904.
256. Bell DS, O’Keefe JH. White cell count, mortality, and metabolic syndrome in the Baltimore longitudinal study of aging. *J Am Coll Cardiol* (2007)50(18):1810.
257. Baalbaki HA, Bell DS. Insulin resistance and thrombogenesis: recent insights and therapeutic implications. *Endocr Pract* (2007)13(6)679-86.
258. Wright JT Jr, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Holdbrook FK, Lukas MA, Iyengar M. Lowering Blood Pressure With beta-Blockers in Combination With Other Renin-Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial. *J Clin Hypertens (Greenwich)*. (2007)9(11):842-849.
259. Bell, DS. Triple oral therapy for type 2 diabetes. *Diabetes Res Clin Pract*. (2007)78(3):313-315.
260. Bell, DSH. Heart failure in the diabetic patient. *Cardiol Clin* (2007)25:523-538.
261. Bell, DSH. Diabetes Update. Audio – Digest *Internal Medicine* (2007)54:23.
262. Bell DS, McGill JB, Fonseca VA. The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statin. *Endocr Pract*. (2007)13(7):808-9.
263. Bell, DSH. Postprandial dysmetabolism as a cardiac risk factor. *Endocrine Today* (2008)6(1)15.
264. Bell DSH, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? *Endocr Pract*(2008)14(1):112-124.
265. Bell, DSH. What is the cause of “dead in bed” syndrome? *Endocrine Today* (2008)6(7)3.

David S.H. Bell

266. **The DREAM Trial Investigators. Effects of ramapril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose. *Diabetes Care* (2008)31:1007-1014.**
267. **Bell DSH. The role of vitamin D for obese patients in reversing the type 2 diabetes pandemic. *Endocrine Today* (2008)6(15)4.**
268. **Bell DS, O'Keefe JH. Use of alternative thresholds defining insulin resistance to predict type 2 diabetes mellitus and cardiovascular disease. *Circulation* (2008)118(11)e156.**
269. **Bell, DS. Diabetes: a cardiac condition manifesting as hyperglycemia. *Endocrine Practice* (2008)14(7):924-932.**
270. **Bell, DSH. Peyronie disease in association with carvedilol: a case report. *Southern Medical Journal* (2008)101(11)1157-1158.**
271. **Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright Jr JT, Iyengar M, Anderson KM, Lukas MA, Bakris GL; for the GEMINI Investigators. Demographic Analyses of the Effects of Carvedilol vs Metoprolol on Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) Study. *J Cardiometab Syndr*. (2008)3(4):211-217.**
272. **Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? *J Am Coll Cardiol*. (2008)52(24):1949-1956.**
273. **Bell, DSH. Hypertension and diabetes – a toxic combination. *Endocrine Practice* (2008)14(8):1031-1039.**
274. **Bell, DSH. Diabetes and cardiovascular risk. *US Endocrinology* (2008)4(1):79-82.**
275. **Bell, DSH. Management of new-onset diabetes mellitus after transplantation. *Postgrad Med* (2009)121(1)161-163.**
276. **Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. *Diabetes Obesity and Metabolism* (2009)11(3)234-238.**
277. **Bell, DSH. Treatment of diabetic hypertension. *Diabetes Obesity and Metabolism* (2009)11(5)433-444.**
278. **O'Keefe JH, Bell DS, Wyne KL. *Diabetes Essentials Fourth Edition* (2009) Jones and Bartlett. Sudbury, MA USA.**

David S.H. Bell

279. Bell, DSH. Importance of postprandial glucose levels in type 2 diabetes. *Southern Medical Journal* (2009)102(5):553.
280. Bell, DSH. The risk of developing coronary artery disease or congestive heart failure and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin or sulfonylureas: a retrospective analysis. *Acta Diabetologia* (2009)102(4)413-415.
281. Bell, DSH. Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome. *SMJ* (2009)102(4)413-415.
282. Bell DS, O'Keefe JH. Metabolic syndrome and postoperative atrial fibrillation (POAF). *Eur Heart J* (2009)30(10)1167-1168.
283. O'Keefe JH, Carter MD, Lavia CJ, Bell DSH. The gravity of JUPITER. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin. *Postgraduate Medicine* (2009)121(3)113-118.
284. Bell DSH, Bruton S, Morales J, White RD. The role of insulin therapy for type 2 diabetes: a primary care roundtable. *Medscape CME* 7/21/2009.
285. Bell, DSH. The association of obesity, metabolic syndrome, diabetes and cardiovascular disease with non-alcoholic fatty liver disease. *Southern Medical Journal* (2009)102(10)991-992.
286. Bell, DSH. Innovative utilization of existing and soon-to-be available therapies for type 2 diabetes. *Joslin Publications*. Boston, USA (2009)2:1-21.
287. Bell DSH, O'Keefe JH. Rediscovering bile acid sequestrants. *Diabetes, Obesity and Metabolism* (2009)11:1114-1125.
288. Bell, DSH. Cardiac considerations in the treatment of the metabolic syndrome. *Heart and Metabolism* (2009)45:20-25.
289. Bell, DSH. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. *Southern Medical Journal*(2010)103(3)265-267.
290. Bell DSH, O'Neill PJ. Hyperandrogenemia in a postmenopausal female that is suppressed with metformin can avoid unnecessary surgery. *The Endocrinologist* (2010)20:83-85.
291. Bell, DSH. Hyperglycemia and ketosis induced by gamma hydroxy-butarate (GHB). *Diabetologia*(2010)53(7)1539-1540.
292. Bell, DSH. Resolution of statin-induced myalgias by correcting vitamin D deficiency. *Southern Medical Journal*(2010)103(7)690-692.

David S.H. Bell

- 293. Bell, DSH. Nocturnal hypoglycaemia presenting as somnambulism. Diabetologia(2010)53:2066-2067.**
- 294. Bell DSH, O'Keefe JH. Metabolic Syndrome Essentials(2011)Jones and Bartlett, Sudbury, MA, USA.**
- 295. Bell, DS. Goals for HbA1c Need To Be Individualized Based on Clinical Judgment, Instead of Third Party Recommendations. Southern Medical Journal(2010)103(9)854-5.**
- 296. O'Keefe JH, Abuannadi M, Lavie CJ, Bell DS. Strategies for optimizing glyemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clinic Proceedings(2011)86(2)128-138.**
- 297. Bell DS, Al Badarin F, O'Keefe JH Jr. Therapies for diabetic dyslipidaemia. Diabetes Obes Metab(2011)13(4):313-25.**
- 298. Bell, DS. Protean manifestations of vitamin D deficiency, part 1: the epidemic of deficiency. Southern Medical Journal(2011)104(5)331-334.**
- 299. Bell, DS. Protean manifestations of vitamin D deficiency, part 2: deficiency and its association with autoimmune disease, cancer, infection, asthma, dermatopathies, insulin resistance and type 2 diabetes. Southern Medical Journal(2011)104(5)335-339.**
- 300. Bell, DS. Protean manifestations of vitamin D deficiency, part 3: association with cardiovascular disease and disorders of the central and peripheral nervous systems. Southern Medical Journal(2011)104(5)340-344.**
- 301. Bell, DSH. Response to "More Adverse Neurological Consequences of Metformin-Induced Vitamin B12 Deficiency". Southern Medical Journal(2011)104(7)542.**
- 302. Bell DS, Dharmalingam M, Kumar S, Sawakhande RB. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficiency demonstration study in the treatment of advanced type 2 diabetes (TriED study -II). Diabetes Obes Metab(2011)13(9)800-805.**
- 303. Bell DS, O'Keefe JH. Lowering the triglyceride-high density lipoprotein cholesterol ratio and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance. J Am Coll Cardiol(2011)58(7)778.**
- 304. Bell, DSH. Why does quick-release bromocriptine decrease cardiac events? Diabetes Obes Metab(2011)13(10)880-884.**
- 305. Morales J, Bell DSH, Funnell M, Branton S. The essential guide to the management of type 2 diabetes. Primary Care Publications Inc. Charlotte, NC (2011)1-54.**

David S.H. Bell

- 306. Bell, DSH. Vitamin D deficiency and diabetes. Practical Diabetology(2011)30(4)6-21.**
- 307. Bell DS. Beware the low urine pH - the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes. Diabetes Obesity Metabolism(2012)14(4)299-303.**
- 308. Bell, DSH. Accuracy of self-mixed small quantities of insulin. Endocrine Practice (2012)18(4)616-617.**
- 309. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol(2012)110(6)826-833.**
- 310. Bell, DSH. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. Postgraduate Med(2012)124(5)121-135.**
- 311. David S. H. Bell. Reversal of the symptoms of diabetic neuropathy through correction of vitamin D deficiency in a type 1 diabetic patient. Case Reports in Endocrinology, vol. 2012, Article ID 165056, 3 pages, 2012.**
- 312. Bell, DS. Combine and conquer. Diabetes, Obesity and Metabolism(2013)15(4)291-300.**
- 313. Bell, DS. Apparent Recurrence of Hyperparathyroidism following Quadruple Parathyroidectomy. Case Rep Endocrinol(2013)2013:912701. Epub 2013 Apr 23.**
- 314. Bell, DS. On the efficacy of CSII for type 2 diabetes. Endocr Pract(2013)19(5)892-893.**
- 315. Bell DSH, Patil HR, O'Keefe JH. Divergent effects of various diabetes drugs on cardiovascular prognosis. Reviews in Cardiovascular Medicine(2013)14(2-4)e107-e122.**
- 316. Bell, DSH. Third party payers fail to recognize the endocrinologist as a specialist. Endocrine Today(2014)12(2):5.**
- 317. Bell, DSH. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep (2014)15:152-154.**
- 318. Bell, DSH. Obesity epidemic: more than just overeating. Endocrine Today(2013)12(5)2.**
- 319. O'Keefe JH, DiNicolantonio JJ, Lavie CJ, Bell DSH. The influence of statins on glucose tolerance and incipient diabetes. US Endocrinology(2014)68-74.**

David S.H. Bell

- 320. Bell DS, DiNicolantonio JJ, O'Keefe JH. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. *Diabetes Obes Metab*(2014)16(8)689-694.**
- 321. Albadarin F, Bell DS, O'Keefe JH. Reply. *Am J Cardiol*(2015)115(6):852-3.**
- 322. Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. *Case Rep Endocrinol*(2015)676191.**
- 323. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. β -Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. *Open Heart*(2015)2(1):e000230.**
- 324. Bell DS. Prevention of Recurrent Nephrolithiasis in Adults. *Ann Intern Med*(2015)162(7):528.**
- 325. Bell DSH. Nondiabetic Neuropathy in a Patient with Type 2 Diabetes. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)361-363.**
- 326. Bell DSH. Severe Distal Symmetrical and Autonomic Neuropathy in a Patient with a Short Duration of Type 1 Diabetes. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)364-366.**
- 327. Bell DSH. Resolution of Infertility with Diabetes Therapy. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)372-374.**
- 328. Bell DSH. Reversal of Insulin-Requiring Type 2 Diabetes and Development of Hypoglycemia in a Morbidly Obese Patient. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)329-331.**
- 329. Bell DSH. High GAD Antibody Levels and Cerebellar Atrophy in a Patient with Type 1 Diabetes. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)369-371.**
- 330. Bell DSH. Somnambulism (Sleepwalking) Caused by Nocturnal Hypoglycemia. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)301-303.**
- 331. Bell DSH. Diabetic Amyotrophy and Neuropathic Cachexia. In *Diabetes Case Studies*. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)367-368.**

David S.H. Bell

- 332. Bell DSH. An Unexplained Decline in HbA1c in Spite of Persistent Hyperglycemia. In Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)90-91.**
- 333. Bell DSH. Almost All Nonobese Young People with an Acute Onset of Diabetes Have Type 1 Diabetes. In Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)70-72.**
- 334. Bell DSH. Type 1 Diabetes Can Present at Any Age. In Diabetes Case Studies. Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association(2015)61-63.**
- 335. Bell, DSH. Significant glycaemic and CV benefits with canagliflozin in T2DM patients. MIMS Hong Kong Endocrinology. May 2015.**
- 336. Bell, DSH. Diabetes therapy and cardiac risk. Cleve Clin J Med(2015)82(3)140.**
- 337. Bell, DS. Type 2 Diabetes. Ann Intern Med(2015) 163(4) 332.**
- 338. Bell DS. Changes seen in gut bacteria content and distribution with obesity: causation or association? Postgrad Med(2015)127(8)863-8.**
- 339. Bell DS. Riceabetes: is the association of type 2 diabetes with rice intake due to a high carbohydrate intake or due to exposure to excess inorganic arsenic? Postgrad Med(2015)127(8)781-2.**
- 340. Bell, DS. Aspirin in the prevention of cardiovascular events in patients with diabetes. Postgraduate Med(2016)128(2)180-90.**
- 341. Bell, DS. The facts about diabetes: eye disease. Empower(2016)1:16-18.**
- 342. Bell, DS. Metformin: A lifesaver for those with and without diabetes. Practical Diabetology(2016)35(1)16-17.**
- 343. Bell, DS. Cutting edge versus cutting cost. Pracial Diabetology(2016)Sept/Oct:12-16.**
- 344. Bell, DS. Statin-induced diabetes: risks, benefits and clinical results. Pracial Diabetology(2016)Nov/Dec:16-19.**
- 345. Bell, DS. Human medicines inappropriately used in animals come at a much lower cost. Southern Medical Journal(2017)110(1)78.**
- 346. Bell, DS. Mechanisms by which metformin improves mortality and hospital readmission in diabetic patients with heart failure. Endocrine Practice(2017)23(3)379.**

David S.H. Bell

- 347. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*(2017)23(Suppl 2):1-87.**
- 348. Bell, DS. Oral pharmacologic treatment of type 2 diabetes. *Annals of Internal Medicine*(2017)167(1)74-75.**
- 349. Bell DSH, Goncalves, E. The Cadillac combination for type 2 diabetes: A GLP-1 receptor agonist and a SGLT2 inhibitor. *Practical Diabetology*(2017)36(3)10-13.**
- 350. Herman ME, O'Keefe JH, Bell DSH, Schwartz SS. Insulin Therapy Increases Cardiovascular Risk: Time for a Sea of Change in Type 2 Diabetes Treatment. *Prog Cardiovasc Dis*(2017)60(3)422-434.**
- 351. Bell, DSH. Re: Diabetic ketoacidosis in patients with type 2 diabetes on SGLT-2 inhibitors: an ongoing concern. *Endocrine Practice*(2018)24(1)126.**
- 352. Goncalves E, Bell DSH. Combination treatment of SGLT2 inhibitors and GLP1 receptor agonists; symbiotic effects on metabolism and cardiorenal risk. *Diabetes Ther*(2018)9(3)919-926.**
- 353. Bell DSH. Finally, after 56 years of type 1 diabetes: a regimen that works. *Postgrad Med*(2018)130(4)409-410.**
- 354. Bell DSH, Goncalves E. Should we still be utilizing warfarin in the type 2 diabetic patient? *Diabetes Obes Metab*(2018) 20(10) 2327.**
- 355. Bell, DSH. Correlation between serum uric acid and diabetic peripheral neuropathy – association rather than causation. *Journal of Neurological Sciences*(2018)390:208 doi: 10.1016.**
- 356. Goncalves E, Bell DSH. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start? *Diabetes Obes Metab*(2017)19(6)909-911.**
- 357. Bell DSH, Goncalves E. Increase in glycated haemoglobin concentrations after unwarranted prescription changes. *Diabetes Obes Metab*(2018)20(10)2510-2511.**
- 358. Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. *Diabetes Obes Metab*(2019)21(2)210-217.**

David S.H. Bell

- 359. Bell DSH, Goncalves E. Heart Failure in the diabetic patient - epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications. Diabetes Obes Metab(2019) Epub ahead of print.**
- 360. Goncalves E, Bell DS. Efficacy of semaglutide versus liraglutide in clinical practice. Diabetes Metab(2019)Oct 11. Epub ahead of print.**
- 361. Bell DS Goncalves E. Case report:efficient avoidance of hospitalization for diabetic ketosis utilizing technosphere inhaled insulin.Diabetes Therapy (2020)11:1175-1177.**
- 362. Bain SC, Bell DSH, Borzi AM, Hamamoto Y, reviewers for Scott LJ Dulaglutide: a review in type 2 diabetes. Drugs (2020)80:197-208.**
- 363. Bell, D.S.H., Goncalves, E. Why Do Falls and Lower Limb Fractures Occur More Frequently in the Diabetic Patient and How Can They Be Prevented? Diabetes Ther(2020)11(8)1687–1694.**
- 364. Bell DSH. Death from diabetes in Ireland/History. Ulster Med J(2020)89(2)130-131.**
- 365. Bell DSH, Goncalves E. Diabetogenic effects of cardioprotective drugs. Diabetes Obes Metab(2021)23(4)877-885.**
- 366. Bell DSH. Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant? Diabetes Ther(2021)12(12)3025-3035.**
- 367. Jerkins T, Bell DSH. Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. Diabetes Ther(2021)12(10)2795-2799.**
- 368. Bell DSH, Goncalves E. Alcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked. Diabetes Ther(2021)12(10)2631-2634.**
- 369. Bell, DSH. Stroke in the patient with diabetes. (Part 1). Diabetes Res Clin Pract(2020)June 164:10.8193.**
- 370. Bell, DSH. Stroke in the patient with diabetes. (Part 2). Diabetes Res Clin Pract(2020)June 164:10.106.**
- 371. Bell DSH, Goncalves E. Alkalinization of the urine and lowering of urine uric acid content in diabetic patients with a low urine pH results in prevention and dissolution of uric acid stones. A case report and retrospective outcome study. Frontiers in Medical Case Reports(2021)2(5)1-4.**
- 372. Bell DSH, Goncalves E. Insulin Pump Therapy: Yesterday, Today and Tomorrow. Frontiers in Medical Case Reports(2021)2(2)1-6.**

373. Bell DSH, Goncalves E. Are There Differences in Potency Between SGLT-2 Receptor Blockers Utilized in The Therapy of Heart Failure? *Frontiers in Medical Case Reports*(2021)2(3)1-2.
374. Bell DSH, Jerkins T. Insulin delivery utilizing hybrid-closed-loop therapy is more effective when a single basal rate rather than multiple basal rates is utilized – A case report. *Frontiers in Medical Case Reports*(2022)3(1)1-4.
375. Bell DSH, Jerkins T. Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient. *Diabetes Ther*(2022)Apr 7.
376. Bell DSH. Metformin induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. *Diabetes Obes Metab*(2022)May 2. doi: 10.1111/dom.14734. Epub ahead of print. PMID: 35491956.
377. Bell DSH. Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy. *J Diabetes Res*(2022)2022:7787732.
378. Bell DSH. Diabetic Mononeuropathies and Diabetic Amyotrophy. *Diabetes Ther*(2022)(10)1715-1722.
379. Bell DSH. Detecting and treating the protean manifestations of diabetic autonomic neuropathy. *Diabetes Obes Metab*(2023)25(5)1162-1173.
380. Jerkins T, McGill JB, Bell DSH. Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. *Diabetes Obes Metab*(2023)Mar 22. doi: 10.1111/dom.15062. Epub ahead of print. PMID: 36949650.